Pentoxifylline and other protein kinase C inhibitors down-regulate HIV-LTR NF-kappa B induced gene expression

D K Biswas1, C M Ahlers, B J Dezube

  • 1Division of Cell Growth and Regulation, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.

Abstract

Insights

Pentoxifylline (PTX) inhibits human immunodeficiency virus type 1 (HIV-1) replication by blocking protein kinase C (PKC)-dependent activation of NF-kappa B. This finding suggests other kinase inhibitors may help manage HIV-1 infection.

Area of Science:

  • Molecular Biology
  • Virology
  • Pharmacology

Background:

  • Pentoxifylline (PTX) is used to treat circulatory disorders.
  • Its anti-human immunodeficiency virus type 1 (HIV-1) mechanism is under investigation.
  • PTX's molecular action against HIV-1 is explored.

Purpose of the Study:

  • To elucidate the molecular mechanism of pentoxifylline's anti-HIV-1 action.
  • To investigate PTX's effect on HIV-1 LTR-regulated gene expression.
  • To determine the role of protein kinases in PTX's antiviral activity.

Main Methods:

  • Studied inhibition of PKC and PKA-mediated activation of HIV-1 LTR reporter gene expression by PTX.
  • Utilized human CD4+ T lymphocytes (Jurkat) and human embryo kidney cells (293-27-2).
  • Employed specific inhibitors for PKC and PKA in cell-free and whole-cell systems to analyze NF-kappa B activation.

Main Results:

  • PTX inhibited PKC- or PKA-catalyzed NF-kappa B activation in cytoplasmic extracts.
  • Calphostin C (PKC inhibitor) reduced NF-kappa B activation and HIV-1 LTR reporter gene expression.
  • H88 (PKA inhibitor) did not affect NF-kappa B action in treated cells, indicating PKC's primary role.

Conclusions:

  • PTX inhibits HIV-1 replication by blocking PKC-dependent activation of NF-kappa B.
  • This mechanism involves inhibiting PMA- or TNF-alpha-induced NF-kappa B activation in Jurkat and 293-27-2 cells.
  • Protein kinase inhibitors may offer a strategy to down-regulate HIV-1 provirus transcription and replication.

Related Concept Videos

Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...